Abcellera Biologics is trading 4.34% up at $11.45 after investors continued rewarding positive Phase 2 results for ABCL635, its menopause-related hot-flash treatment.
- The company priced an oversubscribed $200 million offering on August 13 at $9.75 per share.
- Proceeds will support research, development, and clinical advancement of its pipeline.
- The stock has extended a sharp multi-session rally despite broader U.S. markets trading lower.